Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2018-01-22 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
SC TO-T/A Filing
Regulatory Filings
2018-01-22 English
PRIMARY DOCUMENT
Director's Dealing
2018-01-19 English
SC TO-T/A Filing
Regulatory Filings
2018-01-12 English
FORM 6-K
Board/Management Information Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to SEC rules. The content primarily announces the appointment of a new CEO for Novartis Oncology and an interim leader for the Global Drug Development organization. It is a press release style announcement with no financial statements or detailed financial analysis. The document length is 9018 characters, which is substantial but the content is clearly an announcement of management changes rather than a full management report or financial report. There is no indication of earnings data, audit information, or regulatory certifications. The document fits best under the category of Board/Management Information (MANG) because it announces changes in senior management positions. Therefore, the classification is MANG with high confidence.
2018-01-11 English
Novartis appoints Elizabeth Barrett as Oncology Head
Board/Management Information Classification · 98% confidence The document is a press release from Novartis Finance S.A. announcing management changes: the appointment of Elizabeth Barrett as CEO Novartis Oncology and the interim appointment of Robert Kowalski to lead Global Drug Development. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The presence of contact information for Media Relations and Investor Relations, along with a disclaimer typical of a press release, confirms its nature as a formal corporate announcement, not a full financial report (like 10-K or IR) or a transcript.
2018-01-11 English
M&A Activity 2017
M&A Activity Classification · 100% confidence The document is a letter from legal counsel responding to SEC comment letters regarding a Schedule TO-T filing related to a tender offer by Novartis Groupe France S.A. and Novartis AG for Advanced Accelerator Applications S.A. The letter addresses SEC staff comments on disclosures in the Offer to Purchase document, including minority shareholder rights, legal restrictions, and source of funds. The document references the Schedule TO-T and an amendment to it, which are filings related to tender offers. The content is focused on merger and acquisition regulatory compliance and disclosure, not on financial results, management changes, or other categories. The presence of Schedule TO-T and Offer to Purchase discussions clearly indicates this is related to a tender offer filing. Therefore, the document fits best under the category for M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2017-12-21 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.